Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amicus Therapeutics
(NQ:
FOLD
)
10.71
-0.01 (-0.09%)
Official Closing Price
Updated: 4:15 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amicus Therapeutics
< Previous
1
2
3
4
5
Next >
Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Investors to Contact the Firm
September 17, 2024
From
Kaskela Law LLC
Via
Business Wire
UPDATE -- Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
September 03, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
September 03, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces Participation at the SSIEM 2024 Annual Symposium
September 03, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
May 14, 2024
Via
Benzinga
The Analyst Landscape: 4 Takes On Amicus Therapeutics
December 19, 2023
Via
Benzinga
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
August 30, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 08, 2024
FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates
August 08, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Announce Second Quarter 2024 Financial Results on August 8, 2024
July 30, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product
June 04, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today.
May 14, 2024
Via
Benzinga
FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 09, 2024
FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
May 09, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference
May 08, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
May 01, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
March 20, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Stock Sees RS Rating Improve To 74
March 05, 2024
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday.
Via
Investor's Business Daily
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
March 01, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
February 28, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
February 15, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Stock Sees Improved Relative Strength Rating
February 09, 2024
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday.
Via
Investor's Business Daily
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
February 08, 2024
- Award Recognizes Approval of Amicus Therapeutics’ Two-component Therapy for the Treatment of Late-onset Pompe Disease -
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
February 01, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Time to buy these 3 healthcare companies that raised revenue guidance?
January 16, 2024
The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance.
Via
MarketBeat
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
January 07, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
December 05, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
7 Stocks Most Likely to Follow in WeWork’s Woeful Footsteps
November 15, 2023
These troubled stocks to sell look even worse following WeWork's bankruptcy and will only hurt holders the longer they hold on.
Via
InvestorPlace
Topics
Bankruptcy
Exposures
Financial
Legal
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.